WS
NVO

Wedbush Securities’s Novo Nordisk NVO Stock Holding History

Wedbush Securities’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.92M Sell
81,656
-1,158
-1% -$49.8K 0.1% 156
2026
Q1 		$3.04M Sell
82,814
-150
-0.2% -$7.11K 0.09% 182
2025
Q4 		$4.22M Sell
82,964
-2,730
-3% -$140K 0.12% 126
2025
Q3 		$4.75M Sell
85,694
-694
-0.8% -$40.6K 0.16% 90
2025
Q2 		$5.96M Buy
86,388
+5,470
+7% +$372K 0.21% 74
2025
Q1 		$5.62M Sell
80,918
-1,793
-2% -$148K 0.21% 73
2024
Q4 		$7.12M Sell
82,711
-4,534
-5% -$490K 0.25% 57
2024
Q3 		$10.4M Sell
87,245
-13,582
-13% -$1.81M 0.39% 36
2024
Q2 		$14.4M Buy
100,827
+1,481
+1% +$196K 0.51% 22
2024
Q1 		$12.8M Buy
99,346
+9,226
+10% +$1.1M 0.48% 25
2023
Q4 		$9.32M Buy
90,120
+3,539
+4% +$350K 0.41% 38
2023
Q3 		$7.87M Buy
86,581
+4,115
+5% +$362K 0.39% 42
2023
Q2 		$6.67M Sell
82,466
-4,248
-5% -$347K 0.32% 53
2023
Q1 		$6.9M Buy
86,714
+81,124
+1,451% +$5.75M 0.35% 46
2022
Q4 		$378K Sell
5,590
-72,618
-93% -$4.26M 0.02% 618
2022
Q3 		$3.9M Sell
78,208
-984
-1% -$52.7K 0.22% 70
2022
Q2 		$4.41M Sell
79,192
-290
-0.4% -$16.1K 0.24% 62
2022
Q1 		$4.41M Sell
79,482
-466
-0.6% -$23.9K 0.2% 75
2021
Q4 		$4.48M Buy
79,948
+1,430
+2% +$77.5K 0.19% 86
2021
Q3 		$3.77M Sell
78,518
-922
-1% -$44.6K 0.18% 89
2021
Q2 		$3.33M Buy
79,440
+1,340
+2% +$51.9K 0.16% 108
2021
Q1 		$2.63M Buy
78,100
+1,524
+2% +$54.3K 0.15% 120
2020
Q4 		$2.67M Hold
76,576
– – 0.23% 90
2020
Q3 		$2.66M Sell
76,576
-500
-0.6% -$16.7K 0.25% 84
2020
Q2 		$2.52M Sell
77,076
-228
-0.3% -$7.28K 0.24% 89
2020
Q1 		$2.33M Sell
77,304
-462
-0.6% -$13.8K 0.28% 79
2019
Q4 		$2.25M Hold
77,766
– – 0.2% 116
2019
Q3 		$2.01M Buy
77,766
+774
+1% +$19.6K 0.2% 118
2019
Q2 		$1.97M Sell
76,992
-888
-1% -$21.9K 0.2% 115
2019
Q1 		$2.04M Sell
77,880
-250
-0.3% -$6.14K 0.22% 106
2018
Q4 		$1.8M Buy
78,130
+276
+0.4% +$6.13K 0.23% 102
2018
Q3 		$1.83M Sell
77,854
-508
-0.6% -$12.4K 0.21% 101
2018
Q2 		$1.81M Buy
78,362
+2,506
+3% +$59.6K 0.22% 94
2018
Q1 		$1.87M Buy
75,856
+622
+0.8% +$16.3K 0.24% 95
2017
Q4 		$2.02M Hold
75,234
– – 0.25% 88
2017
Q3 		$1.81M Sell
75,234
-92
-0.1% -$2.08K 0.24% 86
2017
Q2 		$1.61M Buy
+75,326
New +$1.52M 0.21% 101
2016
Q1 		– Sell
-7,296
Closed -$212K – 789
2015
Q4 		$212K Buy
+7,296
New +$202K 0.04% 550
2015
Q2 		– Sell
-20,624
Closed -$551K – 757
2015
Q1 		$551K Buy
20,624
+4,268
+26% +$98.3K 0.09% 251
2014
Q4 		$346K Buy
16,356
+1,070
+7% +$23.9K 0.05% 358
2014
Q3 		$364K Buy
15,286
+2,502
+20% +$57.6K 0.06% 343
2014
Q2 		$295K Buy
+12,784
New +$282K 0.05% 397

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Wedbush Securities's NVO Position: Q2 2026 in Review

Wedbush Securities reduced its Novo Nordisk (NVO) stake by 1.4% in Q2 2026, selling an estimated $49.8K and leaving 81,656 shares worth $3.92M. The position accounts for 0.1% of the portfolio, ranked #156.

Wedbush Securities first reported a position in NVO in Q2 2014 and has held it in 42 quarters since. The position peaked at $14.4M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Wedbush Securities held 81,656 shares of Novo Nordisk worth $3.92M as of Q2 2026.
  • Wedbush Securities sold 1,158 Novo Nordisk shares in Q2 2026, an estimated $49.8K.
  • Novo Nordisk made up 0.1% of Wedbush Securities's portfolio in Q2 2026, its #156 holding.
  • Wedbush Securities first reported a position in Novo Nordisk in Q2 2014 and has held it in 42 quarters since.
  • Wedbush Securities's Novo Nordisk position peaked at $14.4M in Q2 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Wedbush Securities's 13F filing for Q2 2026, filed 28 Jul 2026.